← Drug database

Clopidogrel Acino Pharma GmbH (clopidogrel)

Generic
Region
🇪🇺 EU
Active substance
clopidogrel
Company
Acino Pharma GmbH
Status
Withdrawn
Therapeutic area
Peripheral Vascular Diseases; Stroke; Myocardial Infarction
EU approval
Mon 21 Sep 2009
Designations
Generic
Application
EMEA/H/C/001175
ATC
B01AC04
Official record
www.ema.europa.eu

Indication

Clopidogrel is indicated in adults for the prevention of atherothrombotic events in: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. For further information please refer to section 5.1.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Clopidogrel Acino Pharma GmbH

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.